iRhythm (IRTC) vs LeMaitre Vascular (LMAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
LeMaitre Vascular (LMAT) has outperformed iRhythm (IRTC) over the past year, losing 9.5% versus a loss of 42.7%. Over five years, LMAT leads with a +48.6% price change compared with +41.9% for IRTC. iRhythm is the larger company by market cap ($3.47 billion vs $1.85 billion), about 1.9 times the size.
On valuation, LeMaitre Vascular trades at a lower forward P/E (25.4x vs 82.1x for iRhythm). LeMaitre Vascular pays a dividend yielding 1.11%, while iRhythm does not currently pay one. LeMaitre Vascular converts more of its revenue into profit, with a net margin of 23.1% versus -6.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRTC | LMAT |
|---|---|---|
| Share price | $105.23 | $80.73 |
| Market cap | $3.47B | $1.85B |
| 1-day change | +2.56% | +1.36% |
| YTD return | -42.18% | -1.80% |
| 1-year return | -42.68% | -9.54% |
| 5-year return | +41.93% | +48.64% |
| P/E ratio (TTM) | — | 28.32 |
| Forward P/E | 82.11 | 25.40 |
| EPS (TTM) | $-0.42 | $2.85 |
| Dividend yield | 0.00% | 1.11% |
| Annual dividend | $0.00 | $0.90 |
| Revenue (latest FY) | $747.14M | $249.60M |
| Revenue growth (YoY) | +26.24% | +13.53% |
| Net income (latest FY) | $-44.55M | $57.73M |
| Gross margin | 70.57% | 71.53% |
| Operating margin | -7.68% | 27.21% |
| Net margin | -5.96% | 23.13% |
| 52-week high | $212.00 | $118.01 |
| 52-week low | $100.70 | $78.22 |
| Distance from 52-week high | -50.36% | -31.59% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +65.29% | +32.55% |
| Average volume | 567.98K | 330.14K |
| Shares outstanding | 32.96M | 22.87M |
| Employees | 2,400 | 646 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LMAT has outperformed IRTC by 33.1 percentage points over the past year.
- LeMaitre Vascular offers a meaningfully higher dividend yield (1.11% vs 0.00%).
- LeMaitre Vascular is more profitable, keeping 23.1 cents of every revenue dollar as net income versus -6.0 cents for iRhythm.
- iRhythm grew revenue faster in its latest fiscal year (+26.24% vs +13.53%).
About iRhythm
IRTC stock →iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
Health Care · Medical/Dental Instruments · 2,400 employees
About LeMaitre Vascular
LMAT stock →LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific.
Health Care · Medical/Dental Instruments · 646 employees
IRTC vs LMAT FAQ
Which is bigger, iRhythm or LeMaitre Vascular?
iRhythm (IRTC) is larger, with a market capitalization of $3.47B compared with $1.85B for LeMaitre Vascular (LMAT).
Which stock has performed better over the past year, IRTC or LMAT?
LMAT returned -9.54% over the past 12 months, compared with -42.68% for IRTC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, iRhythm or LeMaitre Vascular?
LeMaitre Vascular pays a dividend yielding 1.11%, while iRhythm does not currently pay a regular dividend.
Are iRhythm and LeMaitre Vascular in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.